Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer

• DOI: 10.1200/jco.2014.55.7348
• Publication Date: 2014-09-16T04:03:03Z
• Authors: Andreas du Bois; Anne Floquet; Jae-Weon Kim; Joern Rau; Josep M. del Campo; Michael Friedlander; Sandro Pignata; Keiichi Fujiwara; Ignace Vergote; Nicoletta Colombo; Mansoor R. Mirza; Bradley J. Monk; Rainer Kimmig; Isabelle Ray-Coquard; Rongyu Zang; Ivan Diaz-Padilla; Klaus H. Baumann; Marie-Ange Mouret...; Jae-Hoon Kim; Christian Kurzeder; Anne Lesoin; Paul Vasey; Christian Marth; Ulrich Canzler; Giovanni Scambia; Muneaki Shimada; Paula Calvert; Eric Pujade-Lauraine; Byoung-Gie Kim; Thomas J. Herzog; Ionel Mitrica; Carmen Schade-Bri...; Qiong Wang; Rocco Crescenzo; Philipp Harter
• Keywords: Pazopanib; Clinical endpoint; Progression-free survival

Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -1/-2/-3, platelet-derived (PDGFR) -α/-β, and c-Kit. Preclinical clinical studies support VEGFR PDGFR as targets for advanced ovarian cancer treatment. This study evaluated the role pazopanib maintenance therapy in patients with whose disease did not progress during first-line chemotherapy.Nine hundred forty histologically confirmed ovary, fallopian tube, or peritoneum, International Federation Gynecology Obstetrics (FIGO) stages II-IV, no evidence progression after primary consisting surgery at least five cycles platinum-taxane chemotherapy were randomized 1:1 to receive 800 mg once per day placebo up 24 months. The end point was progression-free survival by RECIST 1.0 assessed investigators.Maintenance prolonged compared (hazard ratio [HR], 0.77; 95% CI, 0.64 0.91; P = .0021; median, 17.9 v 12.3 months, respectively). Interim analysis based on events 35.6% population show any significant difference. Grade 3 4 adverse hypertension (30.8%), neutropenia (9.9%), liver-related toxicity (9.4%), diarrhea (8.2%), fatigue (2.7%), thrombocytopenia (2.5%), palmar-plantar erythrodysesthesia (1.9%) significantly higher arm. Treatment discontinuation related among treated (33.3%) (5.6%).Pazopanib provided a median improvement 5.6 months (HR, 0.77) who have progressed chemotherapy. Overall data this suggest benefit. Additional should help identify subgroups whom improved efficacy may balance (NCT00866697).